Please wait while the formulary information is being retrieved.
FUZEON (ENFUVIRTIDE)
- HIV infection
90 mg subcutaneous solution
- Inject 1 milliliter (90 mg) by subcutaneous route 2 times per day
HIV infection
- Inject 1 milliliter (90 mg) by subcutaneous route 2 times per day
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- None
Severe
Moderate
- Pneumonia
- Tobacco smoker
FUZEON (ENFUVIRTIDE)
- HIV infection
- Peripheral neuropathy
- Anorexia
- Cough
- Diarrhea
- Ecchymosis
- Erythema
- Fatigue
- Injection site sequelae
- Nausea
- Symptoms of anxiety
More Frequent
Severe
Less Severe
- Acute pancreatitis
- Conjunctivitis
- Eosinophilia
- Pneumonia
- Sinusitis
- Skin nodules
- Acute abdominal pain
- Flu-like symptoms
- Folliculitis
- Herpes simplex infection
- Myalgias
- Pruritus of skin
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Graves' disease
- Guillain-barre syndrome
- Hepatitis
- Hypersensitivity drug reaction
- Localized cutaneous amyloidosis
- Neutropenic disorder
- Polymyositis
- Renal failure
- Steatosis of liver
- Thrombocytopenic disorder
Less Severe
- Constipation
- Depression
- Dysgeusia
- General weakness
- Hematoma
- Insomnia
- Lymphadenopathy
- Paresthesia
- Skin rash
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Enfuvirtide
Use in patients weighing at least 11kg is supported by safety, pharmacokinetic, and efficacy studies in pediatric subjects 6 years of age and older.
Higher incidence of injection site infection in adolescents.
- 1 Day – 6 Years
- Use in patients weighing at least 11kg is supported by safety, pharmacokinetic, and efficacy studies in pediatric subjects 6 years of age and older.
- Higher incidence of injection site infection in adolescents.
- 6 Years – 18 Years
- Use in patients weighing at least 11kg is supported by safety, pharmacokinetic, and efficacy studies in pediatric subjects 6 years of age and older.
- Higher incidence of injection site infection in adolescents.
Enfuvirtide
- Severity Level:
2
- Additional Notes: Insufficient human data available; animal data suggest no developmental toxicity
Contraindicated
Enfuvirtide
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool